Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: Electrophysiological studies in the rat brain

Psychopharmacology

Volumn 232, Issue 13, 2015, Pages 2343-2352

  El Mansari, Mostafa ^a   Lecours, Maurice ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

5 HT1A< inf> receptor; 5 HT1B< inf> receptor; Electrophysiology; Escitalopram; Hippocampus; Serotonin; Vortioxetine

Indexed keywords

5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; ESCITALOPRAM; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; VORTIOXETINE; PIPERAZINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFIDE;

ADULT; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME ACTIVATION; HIPPOCAMPUS; IN VIVO STUDY; MALE; MICROIONTOPHORESIS; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; TRANQUILIZING ACTIVITY; ANIMAL; BRAIN; DRUG ADMINISTRATION; DRUG EFFECTS; ELECTROPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; DRUG ADMINISTRATION SCHEDULE; ELECTROPHYSIOLOGICAL PHENOMENA; HIPPOCAMPUS; MALE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN ANTAGONISTS; SULFIDES;

EID: 84930864010     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-3870-9     Document Type: Article

References (37)

1. Alvarez E, Perez V, Artigas F (2014) Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 10:1297-1307
2. Areberg J, Luntang-Jensen M, Søgaard B, Nilausen DØ (2012) Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 110:401-404
3. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206-3221
4. Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri (2013) The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptors antagonism. Int J Neuropsychopharmacol 16:1115-1127
5. Blier P, Bouchard C (1994) Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol 113:485-495
6. Blier P, De Montigny C (1983) Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3:1270-1278
7. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
8. Blier P, El Mansari M (2013) Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 368:20120536
9. Blier P, De Montigny C, Azzaro AJ (1986) Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 237:987-994
10. Bourke CH, Capello CF, Rogers SM, Yu ML, Boss-Williams KA, Weiss JM, Stowe ZN, Owens MJ (2013) Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. Psychopharmacology (Berl) 228:231-241
11. Brunel S, de Montigny C (1988) Validation of the I.T50 method for assessing neuronal responsiveness to microiontophoretic applications: a single-cell recording study. J Pharmacol Methods 19:23-30
12. Chaput Y, de Montigny C, Blier P (1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 333:342-348
13. Chaput Y, de Montigny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5:219-229
14. Citrome L (2014) Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 68:60-82
15. Czachura JF, Rasmussen K (2000) Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch Pharmacol 362:266-275
16. de Groote L, Klompmakers AA, Olivier B, Westenberg HG (2003) The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Psychopharmacology (Berl) 167:153-158
17. Dremencov E, Gur E, Lerer B, Newman ME (2002) Effects of chronic antidepressants and electroconvulsive shock on serotonergic neurotransmission in the rat hypothalamus. Prog Neuropsychopharmacol Biol Psychiatry 26:1029-1034
18. El Mansari M, Sánchez C, Chouvet G, Renaud B, Haddjeri N (2005) Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30:1269-1277
19. Gobert A, Rivet JM, Cistarelli L, Millan MJ (1997) Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem 68:1159-1163
20. Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ (2013) Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 73:147-159
21. Haddjeri N, Blier P, de Montigny C (1998) Antidepressant treatments tonically activate forebrain 5-HT1A receptors. J Neurosci 18:10150-10156
22. Kandel ER, Spencer WA (1961) Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J Neurophysiol 24:243-259
23. Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215-223
24. Mahableshwarkar A, Zajecka J, Jacobson W, Chen Y, Keefe RSE (2014) Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: Results of a randomized, double-blind, active-referenced, placebo-controlled trial. Int J Psychopharmacol 17(suppl1):016
25. McIntyre RS, Lophaven S, Olsen CK (2013) A randomized, Double-blind, Placebo-controlled Study of Vortioxetine on Cognitive function in depressed adults. Int J Neuropsychopharmacol 17:1557-1567
26. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
27. Mnie-Filali O, Faure C, Lambás-Señas L, El Mansari M, Belblidia H, Gondard E, Etiévant A, Scarna H, Didier A, Berod A, Blier P, Haddjeri N (2011) Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 36:1275-1288
28. Moret C, Briley M (1990) Modulation by drugs of the release of total tritium and 3H-5-HT from rat hypothalamic slices. Naunyn Schmiedebergs Arch Pharmacol 34:398-403
29. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB (2012) P harmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340:666-675
30. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, New York (NY)
31. Pehrson AL, Sanchez C (2014) Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 19:121-33
32. Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C (2013) Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 23:133-145
33. Pineyro G, Blier P, Dennis T, de Montigny C (1994) Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 14:3036-3047
34. Ranck JB (1973) Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson LR (ed) The hippocampus. Plenum Press, New York, pp 207-244
35. Sharp T, Umbers V, Gartside SE (1997) Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121:941-946
36. Stenkrona P, Halldin C, Lundberg J (2013) 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 23:1190-1198
37. Wesołowska A, Nikiforuk A, Stachowicz K (2006) Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur J Pharmacol 553:185-190